Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated September 19, 2024 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary completion date: Jun 1, 2024 to Dec 1, 2024
    • Study completion date: Jul 1, 2024 to Jul 1, 2025
    v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2022 to Feb 1, 2023
    • Site details revised
    v5
  4. Enrollment target: 80 to 120v4 Show 5 more changesShow less
    • Primary completion date: Dec 1, 2022 to Jun 1, 2024
    • Study completion date: Sep 1, 2023 to Jul 1, 2024
    • Eligibility criteria expanded, about 1,046 words
    • Secondary endpoints: 2 to 5
    • Study title expanded, about 4 words
  5. Start date: May 1, 2022 to Jun 1, 2022v3
  6. Start date: Apr 1, 2022 to May 1, 2022v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aimed to evaluate the efficacy, safety, tolerability, feasibility of surgery, and incidence of preoperative and postoperative complications of atezolizumab in combination with platinum-based chemotherapy with resectable stage II-IIIB non-small cell lung cancer.
Trial Details
NCT Number NCT05295212
Lead Sponsor Hunan Province Tumor Hospital
Conditions
(from sponsor)		 Non Small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov